Multivariate analysis of imatinib resistance-related factors during the treatment of chronic myeloid leukemia.
- Author:
Min ZHOU
1
;
Hui-ying QIU
;
Guang-sheng HE
;
Yang XU
;
Jian-nong CEN
;
Jin-lan PAN
;
Su-ning CHEN
;
Ai-ning SUN
;
Ri ZHANG
;
De-pei WU
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Benzamides; therapeutic use; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid, Chronic-Phase; drug therapy; Male; Middle Aged; Piperazines; therapeutic use; Pyrimidines; therapeutic use; Retrospective Studies; Young Adult
- From: Chinese Journal of Hematology 2013;34(5):395-398
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore efficacy of imatinib for patients with chronic myeloid leukemia(CML) and its resistance-related factors during the treatment.
METHODSThe clinical data of 214 CML patients received imatinib were analyzed respectively in our hospital from April 2005 to December 2010. The therapy history and efficacy of regular follow-up and factors influencing drug resistance were analyzed. COX regression analysis was used to perform the univariate and multivariate analysis.
RESULTSUntil the end of follow up, thirty-one patients (14.5%) occurred drug resistance. One of them was in accelerated phase(AP), and two in blast phase(BP); 69.2% of patients achieved a complete cytogenetic response(CCyR), and 31.3% of patients achieved a major molecular response(MMR). COX analysis was performed in 207 chronic phase(CP) patients. Univariate analysis showed that the course of disease before treatment, the hemoglobin count, the white blood cell count, whether achieved CCyR or not and whether achieved MMR or not were the influencing factors for imatinib resistance. Multivariate analysis showed that whether achieved CCyR or not was the independent factor for drug resistance.
CONCLUSIONWhether achieved CCyR or not is an independent factor and also a protective factor for imatinib resistance in patients with CML.
